Molecular diagnosis of citrin deficiency in an infant with intrahepatic cholestasis: identification of a 21.7kb gross deletion that completely silences the transcriptional and translational expression of the affected SLC25A13 allele
Metrics: PDF 1499 views | HTML 2951 views | ?
Zhan-Hui Zhang1,*, Wei-Xia Lin2,*, Qi-Qi Zheng2, Li Guo2 and Yuan-Zong Song2
1Clinical Medicine Research Institute, The First Affiliated Hospital, Jinan University, Guangzhou 510630, China
2Department of Pediatrics, The First Affiliated Hospital, Jinan University, Guangzhou 510630, China
*These authors have contributed equally to this study
Keywords: citrin deficiency, intrahepatic cholestasis, SLC25A13, mutation, Western blotting
Received: December 06, 2016 Accepted: July 18, 2017 Published: August 03, 2017
Neonatal Intrahepatic Cholestasis caused by Citrin Deficiency (NICCD) arises from biallelic SLC25A13 mutations, and SLC25A13 analysis provides reliable evidences for NICCD definite diagnosis. However, novel large insertions/deletions in this gene could not be detected just by conventional DNA analysis. This study aimed to explore definite diagnostic evidences for an infant highly-suspected to have NICCD. Prevalent mutation screening and Sanger sequencing of SLC25A13 gene just revealed a paternally-inherited mutation c.851_854del4. Nevertheless, neither citrin protein nor SLC25A13 transcripts of maternal origin could be detected on Western blotting and cDNA cloning analysis, respectively. On this basis, the hidden maternal mutation was precisely positioned using SNP analysis and semi-quantitative PCR, and finally identified as a novel large deletion c.-3251_c.15+18443del21709bp, which involved the SLC25A13 promoter region and the entire exon 1 where locates the translation initiation codon. Hence, NICCD was definitely diagnosed in the infant. To the best of our knowledge, the novel gross deletion, which silenced the transcriptional and translational expression of the affected SLC25A13 allele, is the hitherto largest deletion in SLC25A13 mutation spectrum. The Western blotting approach using mitochondrial protein extracted from expanded peripheral blood lymphocytes, of particular note, might be a new minimally-invasive and more-feasible molecular tool for NICCD diagnosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.